Omega Marks The Alpha Of Perrigo’s OTC Brand Play
This article was originally published in The Tan Sheet
Executive Summary
The deal expands Perrigo’s distribution footprint from less than 10 to more than 40 countries, but also points toward marketing branded OTCs in some of Omega’s European markets. But another growth driver is in its generic OTC wheelhouse – retailers offering more store brand products, says Perrigo CEO Joseph Papa.
You may also be interested in...
Perrigo’s Pivot To Building Brand Market Share Boosted With Opill OTC Oral Contraceptive Approval
Year after acquiring HRA, Perrigo makes preparations to launch arguably the most anticipated OTC switch in US pharma history, Opill with 0.075-mg norgestel. Analysts estimate $100m annual market for OTC birth control.
Perrigo’s Next CEO Has Long OTC Brands History
Patrick Lockwood-Taylor starts as president/CEO on 30 June, succeeding Murray Kessler as Perrigo awaits FDA decision on subsidiary HRA’s proposal for first US OTC sales of daily oral contraceptive. He’s moving from president of Bayer AG’s US business and regional president, consumer health North America.
Perrigo Reaches Year Anniversary For First OTC Brand Switch With Sixth Packaging Approval
Latest FDA approval for mometasone furoate, 50-mcg metered spray, is for three 144-spray containers. Nasonex 24HR Allergy is Perrigo’s first OTC switch of national brand and first mometasone furoate offered nonprescription in US.